TMEM219

TMEM219 is a cell-surface death receptor that couples binding of its circulating ligand IGFBP-3 to Caspase-8-dependent apoptosis in epithelial and endocrine cell populations, thereby acting as a negative regulator of tissue stem cell and beta cell homeostasis (PMID:26431183, PMID:35115561, PMID:40371646). It is expressed on colonic and intestinal stem cells, pancreatic beta cells and their fetal precursors, and hepatocytes, where IGFBP-3 engagement drives cell loss in a manner independent of IGF-I sequestration (PMID:26431183, PMID:38318298, PMID:42222293). Pro-apoptotic signaling proceeds through Caspase-8 activation, and genetic ablation or tissue-specific deletion of TMEM219, recombinant ecto-TMEM219 decoy protein, or anti-TMEM219 blocking antibodies (e.g. Ent001) restore stem cell self-renewal and beta cell mass and ameliorate diabetic enteropathy, colitis, inflammatory carcinogenesis, and diabetes in preclinical models (PMID:35115561, PMID:40371646, PMID:40783087). Independently of its IGFBP-3 receptor role, TMEM219 is a direct binding partner of IL-13Rα2 within the Chi3l1 signaling complex, where it is required for Chi3l1-stimulated epithelial HB-EGF production and macrophage MAPK/Erk and PKB/Akt activation and contributes to IL-13Rα2 decoy function; Galectin-3 competes with TMEM219 for IL-13Rα2 binding (PMID:27629921, PMID:29427412). TMEM219 expression is post-transcriptionally downregulated by miR-129-2 (PMID:38318298).

1. 2015 High

   Established that TMEM219 acts as a functional IGFBP-3 receptor on colonic stem cells controlling their homeostasis, defining a receptor for a previously orphan ligand activity independent of IGF-I.

   Evidence Patient-derived intestinal organoids and a preclinical diabetic enteropathy model with recombinant ecto-TMEM219 treatment

   PMID:26431183

   Open questions at the time

   • Downstream signaling cascade not yet defined
   • Did not establish the apoptotic effector mechanism
2. 2016 High

   Revealed a second, distinct role for TMEM219 as a direct binding partner of IL-13Rα2 required for Chi3l1-driven MAPK/Erk and Akt signaling, showing the protein participates in a receptor complex beyond IGFBP-3 binding.

   Evidence Yeast two-hybrid, co-IP, BiFC, fluorescence anisotropy nanodisc assays, plus null mutation and siRNA with signaling readouts

   PMID:27629921

   Open questions at the time

   • Relationship between the IGFBP-3 receptor role and the IL-13Rα2 co-receptor role unresolved
   • Stoichiometry within the complex not defined
3. 2018 Medium

   Showed that Galectin-3 competes with TMEM219 for IL-13Rα2 binding, identifying a regulatory input that modulates the antiapoptotic Chi3l1 signaling axis.

   Evidence Biophysical competition and signaling assays in epithelial cells

   PMID:29427412

   Open questions at the time

   • Single-lab competition assay
   • Physiological context of competition not established in vivo
4. 2022 High

   Demonstrated that TMEM219 functions as a death receptor on pancreatic beta cells, connecting IGFBP-3 engagement to beta cell loss and providing a therapeutic rationale for blockade.

   Evidence In vitro and in vivo IGFBP-3/TMEM219 inhibition, TMEM219 genetic ablation, and preclinical diabetes models

   PMID:35115561

   Open questions at the time

   • Molecular link from receptor to caspase activation not detailed
   • Long-term consequences of chronic blockade incompletely characterized
5. 2022 Medium

   Confirmed TMEM219 as a ~22 kDa cell-surface protein in mammalian cells, grounding the receptor model in direct localization data.

   Evidence Stable overexpression in HeLa cells with western blot and flow cytometry

   PMID:35386539

   Open questions at the time

   • No structural information on ligand-binding interface
   • Single-lab overexpression system
6. 2024 Medium

   Extended the death-receptor model to fetal beta cell precursors and identified miR-129-2 as an upstream post-transcriptional regulator of TMEM219, defining a Caspase-8-mediated effector pathway and its regulation.

   Evidence Pharmacological blockade and miR-129-2 mimic/inhibitor experiments in islets and insulinoma cells with Caspase-8 readouts

   PMID:38318298

   Open questions at the time

   • Direct miR-129-2 targeting of TMEM219 transcript not shown mechanistically
   • Single-lab study
7. 2025 High

   Demonstrated through tissue-specific deletion and organoid/antibody blockade that TMEM219-driven Caspase-8 activation mediates intestinal stem cell death in Crohn's disease and that blockade restores regeneration, establishing causality in inflammatory bowel disease.

   Evidence Patient-derived organoids, DSS and T cell colitis models, TMEM219fl/fl LGR5cre mice, ecto-TMEM219 and anti-TMEM219 antibody (Ent001) treatment

   PMID:40371646 PMID:40783087

   Open questions at the time

   • Receptor proximal signaling adaptors upstream of Caspase-8 not identified
   • Antibody data from single lab
8. 2025 Medium

   Implicated IGF-independent TMEM219/Caspase-8 signaling in hepatocyte apoptosis during liver injury and fibrosis, broadening the pathway to liver disease.

   Evidence IGFBP3 overexpression and IGF1-binding mutant in hepatocytes, liver-specific IGFBP3 knockout mice, bile duct ligation rat model, caspase activity assays

   PMID:40853400 PMID:42222293

   Open questions at the time

   • Liver fibrosis evidence is correlative without direct TMEM219 intervention
   • Hepatocyte-specific TMEM219 deletion not tested

• The proximal molecular events linking TMEM219 ligand engagement to Caspase-8 activation, and how the IGFBP-3 death-receptor role integrates with the IL-13Rα2 co-receptor role, remain undefined.
• No identified adaptor or signaling intermediate between receptor and Caspase-8
• No structural model of the IGFBP-3/TMEM219 interface
• Reconciliation of pro-apoptotic and Chi3l1 co-receptor functions unresolved